PDL BioPharma — Q4 2019 Earnings Presentation
16 slides from PDL BioPharma's earnings presentation, Mar 11, 2020
Slide 1: 2019 Fourth Quarter and Full Year Financial Results Conference Call
PDL 2019 Fourth Quarter and Full Year Financial Results Conference Calll March 11, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL’s expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual
Slide 3: Important Additional Information and Where to Find It
Important Additional Information and Where to Find It ‘The Company plans to fle a proxy statement (the "2020 Proxy Statement’) with the U.S. Secunties and Exchange Commission (the "SEC’) in connection with the solicitation of proxies for the Company's 2020 annual meeting of stockholders (the “2020 A
Slide 4: Robust Progress Toward Monetization
Robust Progress Toward Monetization o Disciplined, cost-effective monetization strategy with focus on optimizing return of net proceeds to stockholders o Comprehensive Plan of Complete Liquidation approved by Board enabling potential liquidation tax treatment for distributions o Engaged leading inve
Slide 5: Path to Dissolution
Path to Dissolution o If whole company sale is not consummated, the Company will pursue dissolution as the most efficient wind-down mechanism o Targeting stockholder vote at 2020 Annual Meeting to permit filing of a certificate of dissolution in Delaware = Detailed proposal in 2020 proxy statement o
Slide 6: Rapid Execution Underway
Rapid Execution Underway o Will reduce Board size from 9 at 2019 Annual Meeting to 7 following the 2020 Annual Meeting = Highly experienced with deep expertise in areas important to monetization strategy o Retired 80% of 2021 and 2024 convertible notes in December 2019 = $144M transaction: $98M in c
Slide 7: LENSAR: Innovation Driving Growth
LENSAR: Innovation Driving Growth ° ° ° ° Record Q4-19 net sales of $8.5M = 19% increase from Q4-18 = 5% increase from Q3-19 2019 revenues of $30.7M = 25% increase from 2018 = Exceeded 2019 guidance of $29M Increasingly recognized as technology leader in femtosecond laser-assisted cataract surgery (
Slide 8: LENSAR: Positioned for Sustained Growth
LENSAR: Positioned for Sustained Growth o Best-in-class technology with LENSAR Streamline® IV laser = Enables optimal treatment of tissue-specific cataract and management of astigmatism = 70%-90% of patients who undergo cataract surgery have treatable, visually significant astigmatism, but it remain
Slide 9: LENSAR GEN2: Disruptive New Technology
LENSAR GEN2: Disruptive New Technology o Development of GEN2, a compact, integrated, all-in-one femto-phaco workstation will strengthen LENSAR’s position as the innovation leader o LENSAR intellectual property secures premier technology position for GEN2 development and commercialization o Recent ma
Slide 10: High-Quality Royalty Portfolio
High-Quality Royalty Portfolio Glumetza SAX Depomed \NT indefinite AagyyE AB — 3ykPepomed — <p merc, §/9018 Boehrit iD etien, 206 Ingoramet xr ja nssen JT 9/2023) ‘zoning HO ‘Stowe ree nee eRe, Weems Di Sar, 12/20260 Suse 0 Payoff Cael 4/2022 Cerdelg a Ed SANOFI GENZYME Wy ZAWISC’ AcelRX ee mie Unti
Slide 11: Noden: Focus on Profitability
"1 Noden: Focus on Profitability voven Pr riaraa o Focused on increasing the profitability of Tekturna® (aliskiren) and mitigating the impact of generic competition in the U.S. o Excluding year-end impairment charge, Noden achieved operational profitability with net operating income of $3.4M for 201
Slide 12: Evofem: Value Creation Catalysts in 2020
1" Evofem: Value Creation Catalysts in 2020 o Market value on PDL’s 28% stake in EVFM increased $18.3M for Q4-19 and $36.4M since first investment in April 2019 o Resubmitted Amphora® NDA for prevention of pregnancy in Nov. 2019 o Reported positive topline results from the AMPREVENCE Phase 2b trial
Slide 13: Fourth Quarter 2019 Financials (unaudited)
Fourth Quarter 2019 Financials (unaudited) ‘Three Months Ended ‘Twelve Months Ended December 31, December 31, \Unthousands, exceptper share amounts) 2019 2018 2019 2018 Product revenue, net § 20967 _§ 25975 _§ 85935 _§ 105.448 Royalty rights - change in fair value (25,765) 19,130 (31,042) ___ 85,256
Slide 14: Fourth Quarter 2019 Financials (unaudited)
14 Fourth Quarter 2019 Financials (unaudited) GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) ‘GAP net Joss) income attributed to PDL's shareholders, as reported ‘Adjustments: Markcto-market adjusim entto Birvalue -royaltyassets Markcto-market adjusim ents to equityaffiate -common s
Slide 15: Fourth Quarter 2019 Financials (unaudited)
Fourth Quarter 2019 Financials (unaudited) Consolidated balance sheet data (in thousands) Cash and cash equivalents Notes receivable Royalty rights - at fair value Investment in equity affiliate Intangible assets, net Total assets Convertible notes payable Total stockholders’ equity December 31, $ $
Slide 16: Questions & Answers
PDL Questions & Answers